T-Therapeutics
Latest round
- Series B
Last raised
- Nov 2026
Total raised
- $217M
Investors
- 21
About T-Therapeutics
Based in Cambridge, UK, and founded by Allan Bradley (CEO and Board Director) in 2022, T-Therapeutics Limited, a spin-off from the University of Cambridge, operates as a biotechnology company specializing in T cell receptors (TCR). The company (as of November 2023) is working on the development of TCR-based drugs through its proprietary OpTiMus® platform for cancer patients. The OpTiMus® platform is a humanized TCR mouse, that generates unique, fully human TCRs not found in the human repertoire. This innovation allows T-Therapeutics to identify 'optimal' TCRs as the foundation for cancer therapies. By harnessing the natural power of T cells, these drugs aim to recognize specific cancers and mobilize the patient's own T cells to eliminate cancer cells, ultimately eradicating tumors.
Who invested in T-Therapeutics
21 investors across 3 rounds
See all investors in T-Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about T-Therapeutics
Who invested in T-Therapeutics?
T-Therapeutics has 21 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has T-Therapeutics raised?
T-Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did T-Therapeutics last raise money?
T-Therapeutics's most recent round on record is a Series B, in Nov 2026.
What does T-Therapeutics do?
Based in Cambridge, UK, and founded by Allan Bradley (CEO and Board Director) in 2022, T-Therapeutics Limited, a spin-off from the University of Cambridge, operates as a biotechnology company specializing in T cell receptors (TCR).
Where is T-Therapeutics headquartered?
T-Therapeutics is headquartered in Cambridge, UK.
Which VCs invest in companies like T-Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at T-Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like T-Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.